Gout Market to Accelerate Positively, Estimates DelveInsight | Key Companies Active in the Market - InventisBio, Allena, Olatec, Shanton, LG Chem, Arthrosi, Jiangsu Hengrui Medicine, AstraZeneca, R-Pharm, Arrowhead, Horizon

The gout market is predicted to propel in the 7MM during the forecast period (2023–2032) owing to the increase in the prevalent cases of gout, along with the expected launch of emerging therapies by key companies such as  InventisBio Co., Allena Pharmaceuticals, Olatec Therapeutics, LG Chem, and others.

LAS VEGAS, July 4, 2023 /PRNewswire/ -- DelveInsight's Gout Market Insights report includes a comprehensive understanding of current treatment practices, gout emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Gout Market Report

• As per DelveInsight analysis, the gout market is expected to grow positively at a significant CAGR during the study period (2019–2032).
• According to the secondary research the US is expected to account for the highest cases of gout among the 7MM,and these cases are expected to rise in the forecasted period (2023–2032).
• Globally, leading gout companies such as Jiangsu Hengrui Medicine, Selecta Biosciences, LG Chem, Shanton Pharma, TWi Biotechnology, Olatec Therapeutics, Allena Pharmaceuticals, JW Pharmaceutical, Revive Therapeutics, Hinova pharmaceuticals, Arthrosi Therapeutics, Dyve Biosciences, Jiangsu Atom Bioscience and Pharmaceutical, Swedish Orphan Biovitrum, Allen Pharmaceuticals, Teijin Pharma, AstraZeneca, R-Pharm, InventisBio, Nippon Chemiphar, Sinovent, Shenyang Sunshine Pharmaceutical, Rigel Pharmaceuticals, Chongqing Fochon Pharmaceutical, Alnylam Pharmaceuticals, Enzychem Lifesciences, Arrowhead Pharmaceuticals, Horizon Therapeutics, and others are developing novel gout drugs that can be available in the gout market in the coming years.
• Some key therapies for gout treatment include D-0120 + Allopurinol, ALLN-346, Dapansutrile, SAP001, Tigulixostat, AR882, and others.

Discover which therapies are expected to grab the major gout market share @ Gout Market Report

Gout Overview

Gout is a type of inflammatory arthritis that is quite frequent. It is caused by a crystal known as uric acid. Gout is characterised by joint pain and edoema in one or more joints. The big toe is usually affected. However, it can also be present in other joints such as the knee, ankle, foot, hand, wrist, and elbow. Men are more likely to be affected than women. Gout typically appears in middle age. A gout attack is an incident of gout. Gout episodes are excruciatingly painful and can occur unexpectedly, frequently overnight. Symptoms in the afflicted joint(s) during a gout attack may include: pain, redness, and stiffness. Swelling, soreness, even to gentle contact, such as a bedsheet, warmth, or the sensation that the joint is "on fire." A gout episode can linger for a week or more. You may have no symptoms in between gout bouts.

Some people get gout attacks on a regular basis, while others go years without experiencing one. Gout bouts may become more frequent and persist longer if not addressed. Gout attacks can occur repeatedly in the same joint or in separate joints. Some gout patients report that an episode begins with a burning, itching, or tingling sensation in a joint an hour or two before the flare-up occurs. The joint may feel stiff or a little sore.

Gout Epidemiology Segmentation

The gout epidemiology section provides insights about the historical and current gout patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. 

The gout market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Gout Prevalent Cases
• Gout Gender-specific Prevalent Cases
• Gout Age-specific Prevalent Cases
• Gout Diagnosed and Treatable Cases

Gout Treatment Market 

The goal of treatment during an acute gout episode is to reduce inflammation and decrease discomfort. Uratelowering treatment, which keeps serum urate (sUA) levels below 5 to 6mg/dL, is beneficial for controlling chronic gout. According to ACR guidelines, allopurinol is the first-line treatment for gout. However, 10-30% of patients do not respond and are intolerant to allopurinol. The FDA recently issued a black box warning for febuxostat's cardiovascular risk. Pegloticase is a third-line medication for severe gout or those who have failed conventional therapy due to its poor tolerability. There is currently no gout medicine that regularly decreases serumurate levels below 5 mg/dL to yield clinical advantages such as flare and/or tophi reduction.

NSAIDs, colchicine, or corticosteroids (systemic or intra-articular) can be used to treat pain and inflammation. The decision of whether gout treatment is best for a specific patient should be based on the patient's co-morbid medical problems, other drugs, and side effect profile. NSAIDs that are commonly used during an acute gout attack include ibuprofen 800 mg three to four times per day or indomethacin 25 to 50 mg four times per day. When the symptoms have subsided, the gout treatment should be stopped. Because intravenous colchicine is associated with substantial toxicities and adverse effects, it should only be administered orally. Because of GI side effects, high doses of oral colchicine are often poorly tolerated. Lower doses are well tolerated and can be used in conjunction with NSAIDs.

To know more about gout treatment, visit @ Gout Treatment Drugs 

Key Gout Therapies and Companies

• D-0120 + Allopurinol: InventisBio Co., Ltd
• ALLN-346: Allena Pharmaceuticals
• Dapansutrile: Olatec Therapeutics LLC
• SAP001: Shanton Pharma Co., Ltd.
• Tigulixostat: LG Chem
• AR882: Arthrosi Therapeutics

Learn more about the FDA-approved drugs for gout @ Drugs for Gout Treatment 

Gout Market Dynamics

The dynamics of the gout market are expected to change in the coming years. The rising prevalence of the disease is the prominent factor boosting the growth of the gout market. In addition, the increase in healthcare spending and rising R&D activities are also likely to propel the gout market in the next few years. Furthermore, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the gout market in the 7MM.

However, several factors are impeding the growth of the gout market. The Gout market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the gout market growth.

Scope of the Gout Market Report

• Therapeutic Assessment: Gout current marketed and emerging therapies
• Gout Market Dynamics: Attribute Analysis of Emerging Gout Drugs
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Gout Market Access and Reimbursement

Discover more about gout drugs in development @ Gout Clinical Trials

Table of Contents

Related Reports

Chronic Gout Epidemiology Forecast

Chronic Gout Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted chronic gout epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Gout Pipeline

Gout Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key gout companies, including Jiangsu Hengrui Medicine, Selecta Biosciences, LG Chem, Shanton Pharma, TWi Biotechnology, Olatec Therapeutics, JW Pharmaceutical, Revive Therapeutics, Hinova pharmaceuticals, Arthrosi Therapeutics, Dyve Biosciences, Jiangsu Atom Bioscience and Pharmaceutical, Swedish Orphan Biovitrum, among others.

Chronic Gout Market

Chronic Gout Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic gout companies, including Hinova pharmaceuticals, Arthrosi Therapeutics, Dyve Biosciences, Jiangsu Atom Bioscience and Pharmaceutical, Swedish Orphan Biovitrum, among others.

Chronic Gout Pipeline

Chronic Gout Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic gout companies, including Hinova pharmaceuticals, Arthrosi Therapeutics, Dyve Biosciences, Jiangsu Atom Bioscience and Pharmaceutical, Swedish Orphan Biovitrum, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
info@delveinsight.com  
+1(919)321-6187
www.delveinsight.com 

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg